Gilead dangles $105M in quick cash to sign Scholar Rock to a discovery deal for its growing NASH pipeline

At last count Gilead $GILD had 3 clinical stage programs for NASH in the pipeline, topped by their Phase III work on selonsertib.

But that’s not enough.

Today the big biotech — which is getting a brain transplant in the executive suite as Roche’s Daniel O’Day heads for the helm — added a discovery program with Scholar Rock $SRRK on a slate of TGFβ inhibitors for fibrotic diseases, beefing up a portfolio of drugs that encompass NASH and diabetic kidney disease.